Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. RYAH Group, Inc.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

DECEMBER 14, 2021

(“IGC” or the “Company”) today announced positive primary endpoint data for its Phase 1 clinical trial for IGC-AD1, which is a proprietary cannabinoid-based investigational new drug candidate for patients who have Alzheimer’s disease. The trial was conducted as a multiple ascending dose (MAD) study.

Clinical Trials 52

Clinical Trials Safety Data Patients 52

The Cannigma

APRIL 12, 2023

MoreBetter, creators of the Releaf App, is using this real world data to push back against the claim that there’s no evidence that CBN can help people sleep. In September 2021, MoreBetter hosted a self-reported data collection with this CBN tincture offered to participants for free of charge from CBDistillery. Here’s what they found.

Sleep 133

Sleep Data Tincture Research and Development 133

Cannabis Law Report

JUNE 21, 2021

Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Men were more likely than women to treat pain with cannabis.

Data 105

Data Clinical Trials Research and Development Indica 105

Cannabis Law Report

DECEMBER 2, 2021

(IGC) is excited to present preliminary positive secondary end point findings from its Phase 1 clinical trial for IGC-AD1. The results of the clinical trial have been submitted in the Clinical/Statistical Report (“CSR”) filed with the FDA, and relevant data is also available on Form 8-K filed with the SEC on December 2, 2021.

Clinical Trials 52

Clinical Trials Data Patients THC 52

Cannabis Law Report

JUNE 29, 2021

We look forward to his expertise as we expand our mental health analytical platform and enter clinical trials. Our main product is the Ehave Dashboard which is a mental health informatics platform that allows clinicians to make objective and intelligent decisions through data insight using Blockchain technology. Ehave, Inc.

Clinical Trials 105

Clinical Trials Research and Development Data Patients 105

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 84

Clinical Trials Pharmaceutical Research and Development Cannabinoids 84

NORML

APRIL 30, 2020

The call for comments, posted on April 17 at regulations.gov here , states: “Interested persons or organizations are invited to participate by submitting written views, recommendations, and data related to perspectives on and experiences with pain and pain management. percent in 2016).”

Chronic Pain 341

Chronic Pain Clinical Trials Data Patients 341

NORML

MARCH 30, 2020

There is an absence of clinical data supporting the efficacy of CBD as an antiviral agent, according to a systematic literature review published in the journal Cannabis and Cannabinoid Research. However, this data was based solely on preclinical findings. ” — appears online here.

CBD 295

CBD Clinical Trials Data Treatment 295

SpeedWeed

MARCH 30, 2021

THE UK’s first National Health Service patients registry will start collating data from Thursday this week in a significant move for medical cannabis in the country. The development has been welcomed and comes as the nation’s doctors are said to be shifting their cultural stance from viewing ‘cannabis as a dirty word’.

Data 52

Data Patients Clinical Trials Business 52

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. Flora Pharma expects to fast track traditional FDA and NHS timelines by running phase trials in parallel (in vitro, in vivo, pilot in human, safety/efficacy, etc.).

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

JULY 27, 2021

His first initiative is co-authoring an original study on epilepsy using survey data gathered from RoC’s innovative Observational Research Registry (ORR). Schlienz, a clinical psychologist, led the development of the ORR as a postdoctoral research fellow at Johns Hopkins University. About Realm of Caring.

Data 105

Data Epilepsy Research and Development Clinical Trials 105

Cannabis Law Report

OCTOBER 28, 2021

Psymposia report… O n Sep 23, 2021, Psymposia staff received an email from the personal email account of Mark Haden — the former Executive Director of psychedelic nonprofit MAPS Canada and current Director of Clinical Trials for Psygen Inc. MAPS Canada’s Data Breach Foreshadows Corporadelic Future.

Data 52

Data Clinical Trials Events Medicine 52

Cannabis Law Report

JUNE 4, 2021

Nasdaq: AIKI ) (“AIkido” or the “Company”) today announced that positive Phase 1 testing data was presented at the 2021 ASCO Annual Meeting June 4 , 2021. Clinical trial information: NCT03276572 ( [link] ). NEW YORK , June 4, 2021 /PRNewswire/ — AIkido Pharma Inc. Abstract Number: 5015.

Data 100

Data Research and Development Clinical Trials Therapy 100

Cannabis Law Report

DECEMBER 27, 2019

If you thought there was no relationship between cannabis use and technology, consider these stats: the average number of mobile apps being used in a day by current cannabis users are 4. Virtual Clinical Trials transcend geographic, mobility and economic barriers. Authored By : Arundati Dandapani.

Clinical Trials 85

Clinical Trials Access Research and Development Supply Chain 85

Puff Puff Post

MARCH 10, 2020

InMed and CHDR are currently preparing the Clinical Trial Application for a second Phase 1 clinical trial (755-102-HV), planned to begin in the second quarter of 2020, which will examine the local safety of INM-755 on small areas of wounded skin in healthy volunteers.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

NORML

JANUARY 31, 2019

Seventy-five percent of military veterans say that they would consider using either “cannabis or cannabinoid products as a treatment option,” according to member survey data compiled by the group Iraq and Afghanistan Veterans of America (IAVA). The organization represents over 400,000 veterans nationwide.

Clinical Trials 193

Clinical Trials Chronic Pain Data Treatment 193

Cannabis Law Report

SEPTEMBER 13, 2021

(Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021. in the blood. Chief Scientific Officer. MyMD Pharmaceuticals, Inc.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

Cannabis Law Report

JULY 7, 2021

New data shows MYMD-1 has key differentiators and capabilities compared to existing TNF inhibitor drugs. Company plans to initiate Phase II trial with a leading academic institution. These advanced analytics provide a human-centric, data-driven approach to phenotypic discovery for clients.”.

Pharmaceutical 105

Pharmaceutical Data Clinical Trials Research and Development 105

Veriheal

JANUARY 11, 2023

Gaize is mastering the art of cannabis impairment detection. The Missoula, Montana-based company is gearing up for the launch of its first science-backed real-time cannabis impairment detection device. Studies on cannabis have shown that the plant may cause disorientation, sedation, lack of concentration, and impaired judgment.

Clinical Trials 98

Clinical Trials THC Data Safety 98

Cannabis Law Report

JUNE 2, 2021

Researchers studying the efficacy of marijuana treatments for veterans’ mental health now have access to $20 million in marijuana tax revenue to fund clinical trials. Department of Veteran Affairs’ most recent data. None of it was initially slated to go to clinical trials. Between Dec. Read more at.

Clinical Trials 105

Clinical Trials Marijuana Recreational Collective 105

Cannabis Law Report

DECEMBER 3, 2021

We are honored to be at the AES Meeting this year after almost a year of planning from our medical and scientific affairs, clinical, and advocacy teams, with nine presentations spanning our IV and oral portfolio—Marinus’ largest data showing to date,” said Scott Braunstein, M.D., Chief Executive Officer of Marinus Pharmaceuticals. “We

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

Veriheal

AUGUST 22, 2022

Clinical trials into cannabis’ potential as an opioid replacement are well underway in South Africa. ” Dr. Gallow prides himself on his work as a South African cannabis advocate and leader in the international medical cannabis research field. It has been fairly slow,” explained Dr. Gallow.

Clinical Trials 113

Clinical Trials Chronic Pain Hydroponic Strains 113

Veriheal

JUNE 30, 2023

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. For their analysis, researchers conducted qualitative interviews with 13 individuals who had participated in a psilocybin clinical trial.

Clinical Trials 98

Clinical Trials Research and Development Therapy Policy 98

Cannabis Law Report

JULY 25, 2022

Mindbio Therapeutics , a subsidiary of cannabis and psychedelics holding company Blackhawk Growth Corp. million ($650,000) in funding from New Zealand’s Health Research Council (HRC) to conduct a LSD microdosing trial in patients with Major Depressive Disorder (MDD). Press Release. mentalhealth #help #lsd #menta … [link].

Microdosing 52

Microdosing Clinical Trials Research and Development Data 52

Veriheal

FEBRUARY 9, 2023

A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. All imaging and behavioral data will be accessible to the public after the study is complete. What Is an MRI?

Clinical Trials 98

Clinical Trials Research and Development Data Collective 98

Cannabis Law Report

SEPTEMBER 22, 2021

Data indicates potential of drug candidate to deliver an extremely potent therapeutic benefit at a very low non-toxic dose. New data will be presented at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston. We look forward to providing continuing updates as we advance this drug candidate in the clinic.”.

Pharmaceutical 52

Pharmaceutical Data CBD Clinical Trials 52

Cannabis Law Report

JUNE 19, 2022

The market for psychedelic substances is projected to grow rapidly, potentially outpacing the legal US cannabis market. For example, compounds such as psilocybin, mescaline, ibogaine, and LSD are being evaluated in clinical trials, but the compounds themselves are unpatentable because their existence is well documented in the prior art.

Clinical Trials 52

Clinical Trials Microdosing Data Pharmaceutical 52

Project CBD

MARCH 21, 2023

The CBD she took may or may not have helped, but according to a recent survey of tinnitus patients, she wasn’t alone in trying — or at least in being interested in cannabis as a potential remedy. Among the 45 respondents, median age 55, only 10 said they were current cannabis users (19 had never used, and 16 had used in the past).

Cannabinoids 144

Cannabinoids Clinical Trials Sleep Blood Pressure 144

Cannabis Law Report

NOVEMBER 20, 2019

Since a new law took effect a year ago, England’s National Health Service (NHS) has reimbursed patients on only 18 occasions for “unlicensed” cannabis-based products that have not undergone clinical trials, according to government data. All other cannabis-based medicines are unlicensed. Read the full story.

Clinical Trials 45

Clinical Trials Data Medicine Patients 45

Cannabis Law Report

MAY 10, 2022

First comprehensive study reveals why Australians take medicinal cannabis. First academic study of national medicinal cannabis data. The first in-depth study of Australia’s medicinal cannabis program, which began in 2016, shows the drug is being increasingly prescribed for various conditions. 11 May 2022.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

MAY 10, 2022

Anxiety and sleep disorders were some reasons given for prescriptions despite lack of evidence for cannabis treatment, researchers find. The researchers’ analysis found anxiety was the reason given for 16% of medicinal cannabis prescriptions. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

JUNE 19, 2022

Partnership will focus on the collection and analysis of digital biomarkers to identify signs of response and relapse in upcoming Phase 2 clinical trials. However, we need rigorous clinical trials to ensure that this promise is realised. June 14, 2022 02:00 AM Eastern Daylight Time.

Clinical Trials 52

Clinical Trials Patients Research and Development Treatment 52

Cannabis Law Report

JULY 7, 2021

The Canadian weed giant marked a milestone in Germany this week, harvesting the country’s first medical cannabis crop. Tilray is embarking on a push to educate more German doctors about the benefits of prescribing medical cannabis, as the weed giant seeks to cement its dominance in the highly-profitable European medical market.

Clinical Trials 105

Clinical Trials Education Data Pharmaceutical 105

The Cannigma

JUNE 14, 2021

For more than 50 years, if you wanted to do cannabis research in the United States, federal law said you had to get the cannabis from the University of Mississippi. The BRC is among the dozens of organizations that have received preliminary approval from the DEA to cultivate cannabis.

DEA 133

DEA Research and Development Clinical Trials Pharmaceutical 133

The Cannigma

FEBRUARY 2, 2021

This article was originally published on Analytical Cannabis and appears here with permission. . In a new survey of German patients with Parkinson’s disease, 8% of patients reported using cannabis products. Of these consumers, over half said the drug had a beneficial clinical effect on their condition.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

Veriheal

MAY 26, 2022

With new and improved products popping up left and right, legalization initiatives taking off all over the globe, and harmful “stoner” stigmas quickly dissipating, it’s clear that cannabis has entered a new era. The days of “reefer madness” are long over, replaced by a growing acknowledgment of the cannabis plant’s therapeutic abilities.

Advocacy 98

Advocacy Patients Clinical Trials Education 98